Q4 performance declined year-on-year, Imeik Technology Development continues to increase investment in research and development | Interpretations

① In 2024, Imeik Technology Development's revenue and Net income growth rates both fell to single digits, and in Q4, there was even a decline in performance. ② The company continues to increase its investment in research and development, with products like injectable botulinum toxin type A entering the registration application stage.

cls.cnMar 19 11:03 ET

Is Imeik Technology Development's premium of 13 times for controlling the leading aesthetic medical brand in South Korea too high?| K Commentary

① Imeik Technology Development holds a 13 times premium stake in South Korea's REGEN Biotech, which possesses two core products, AestheFill and PowerFill; ② If Imeik Technology Development wants to reclaim exclusive agency rights for AestheFill in China from JiangSu WuZhong Pharmaceutical Development, certain costs will inevitably need to be incurred; ③ The competition in the medical beauty regeneration sector is intensifying, and recently two hydroxyapatite products have been approved.

cls.cnMar 13 07:57 ET

A total scale of 30 billion! The first national-level mother fund in the foreign trade and economic field is being raised, introducing listed company LP Jinbo Bio and Joinn Laboratories.

① The Innovation and Development Guidance Fund for Service Trade is a national-level fund initiated by the Ministry of Finance, the Ministry of Commerce, and China Merchants Group, approved by the State Council, with a total scale of 30 billion yuan. ② An IR practitioner stated to the Star Daily that the second phase of the service trade fund inviting listed companies to become LPs may be a more market-oriented signal.

cls.cnDec 13, 2024 05:33 ET

Q3 revenue growth rate dropped to 1%. Can the next approved botox product in China be featured on imeik technology development? | Interpretations

①In the first three quarters, imeik technology development's performance has shown some growth, but the revenue and net income attributable to shareholders have slowed down. ②In order to seek new growth points, imeik technology development's research and development expenses continue to rise, focusing on the layout of weight management drugs, botulinum toxin and other fields.

cls.cnOct 23, 2024 11:43 ET

imeik technology development Q3 revenue increased by 1.10% year-on-year, net income increased by 2.13% | Financial Report Watch

In the first three quarters, the company achieved revenue of approximately 2.376 billion yuan, a year-on-year increase of 9.46%; net income was approximately 1.586 billion yuan, a year-on-year increase of 11.79%. The operational scale of the company is steadily increasing, and the profitability meets market expectations.

wallstreetcnOct 23, 2024 09:43 ET

Revenue and net profit growth rates have both slowed down. Is Jinbo Life Sciences, which has been frequently accused, feeling the pressure? | interpretations

①In the first three quarters of this year, Jinbo Bioscience's performance still maintained a high-speed growth, but the growth rate slowed down compared to the same period last year. ②In addition, the rapid growth of the company's sales expenses was caused by reasons such as the expansion of the sales team. ③The company's core product, Weiyi Mei, is facing multiple pressures, so Jinbo Bioscience has frequently stated its posture in the face of internet-related sales platforms.

cls.cnOct 21, 2024 12:03 ET